#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Marginal zone lymphoma refractory Astrocytoma Loeys-Dietz syndrome ABO haemolytic disease of newborn Uveal melanoma Squamous cell carcinoma of the oral cavity Hypoxic-ischaemic encephalopathy Optic glioma Type IIa hyperlipidaemia Autoimmune demyelinating disease Cervix carcinoma recurrent Short stature homeobox gene mutation Ovarian cancer stage III Chondrosarcoma metastatic Warm autoimmune haemolytic anaemia More trials…

    Learn about Rare Diseases

    Hereditary angioedema with C1 esterase inhibitor deficiency – Life with Disease Primary immunodeficiency syndrome – Diagnostics Propionic acidaemia – Treatment Glycogen storage disease type I – Trials in Disease Extranodal marginal zone B-cell lymphoma (MALT type) – Treatment Lymphangiosarcoma – Basic Information Indolent systemic mastocytosis – Diagnostics Antithrombin III deficiency – Diagnostics Small intestine leiomyosarcoma – Life with Disease Metachromatic leukodystrophy – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Bimekizumab IMA401 GRNA1599 Naloxone Hydrochloride POLYSORBATE 80 Flucloxacillin Vx-522 Prasugrel Riociguat Mva-209-Fsp-B3 SODIUM TETRACHLOROPALLADATE Isotretinoin VHB937 Staphylococcus Aureus Fidanacogene Elaparvovec Exemestane Quemliclustat Emrusolmin Orlistat E.coli Polysaccharide More therapies…

    Learn about Your Condition

    Thrombocytopenia Uterine leiomyosarcoma Biopsy heart Myeloproliferative neoplasm Spondylolisthesis Osteoarthritis Chronic coronary syndrome Facial paresis Neuropathy peripheral Schizoaffective disorder Prostate cancer recurrent Procedural anxiety Developmental hip dysplasia Tuberculosis Spinal pain More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Human epidermal growth factor receptor negative

  • A Study Comparing GDC-4198 Alone and with Giredestrant versus Abemaciclib with Giredestrant for Advanced Breast Cancer After Previous CDK4/6 Treatment

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Human epidermal growth factor receptor negative
    • Hormone receptor positive breast cancer
    • Breast cancer
    Investigated Drugs:
    • Giredestrant
    • Abemaciclib
    France Germany Italy Spain

  • Study of Simvastatin with Nivolumab and Oxaliplatin for Patients with Advanced Stomach or Esophageal Cancer with ARID1A Mutation

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Human epidermal growth factor receptor negative
    • Gastrooesophageal cancer
    Investigated Drugs:
    • Simvastatin
    • Capecitabine
    • Fluorouracil
    Italy

  • Study of Patritumab Deruxtecan and Pembrolizumab for Patients with High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Human epidermal growth factor receptor negative
    • Triple negative breast cancer
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Patritumab Deruxtecan
    • Epirubicin Hydrochloride
    • Capecitabine
    Spain

  • Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Elacestrant
    • Ribociclib
    Austria Germany Spain

  • Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Human epidermal growth factor receptor negative
    • Breast cancer female
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Ribociclib
    Germany

  • Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Fulvestrant
    • Giredestrant
    • Abemaciclib
    Austria Belgium Finland France Germany Greece +7
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!